Edition:
United States

Zafgen Inc (ZFGN.OQ)

ZFGN.OQ on NASDAQ Stock Exchange Global Select Market

5.28USD
1:14pm EST
Change (% chg)

$-0.20 (-3.65%)
Prev Close
$5.48
Open
$5.42
Day's High
$5.46
Day's Low
$5.23
Volume
21,408
Avg. Vol
79,855
52-wk High
$12.35
52-wk Low
$3.61

Latest Key Developments (Source: Significant Developments)

Zafgen Inc Files For Mixed Shelf Of Up To $200 Million
Friday, 9 Nov 2018 04:54pm EST 

Nov 9 (Reuters) - Zafgen Inc ::ZAFGEN INC FILES FOR MIXED SHELF OF UP TO $200 MILLION – SEC FILING.  Full Article

Zafgen Announces Proposed Offering Of Common Stock
Wednesday, 27 Jun 2018 04:01pm EDT 

June 27 (Reuters) - Zafgen Inc ::ZAFGEN ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.  Full Article

Zafgen Says Co Entered Into Loan And Security Agreement Providing For Term Loan With Principal Amount​ Of $20 Mln
Friday, 5 Jan 2018 05:04pm EST 

Jan 5 (Reuters) - Zafgen Inc ::ZAFGEN SAYS ‍ON DEC 29, CO ENTERED INTO LOAN AND SECURITY AGREEMENT PROVIDING FOR TERM LOAN WITH PRINCIPAL AMOUNT​ OF $20 MILLION - SEC FILING.  Full Article

Zafgen Reports Strong Clinical Progress And Updates Outlook For 2018
Friday, 5 Jan 2018 07:00am EST 

Jan 5 (Reuters) - Zafgen Inc ::ZAFGEN REPORTS STRONG CLINICAL PROGRESS AND UPDATES OUTLOOK FOR 2018.ZAFGEN- INCREASED CASH POSITION DURING Q4, EXPECTS TO END CALENDAR YEAR 2017 WITH OVER $100 MILLION IN CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES.ZAFGEN INC - WELL-CAPITALIZED TO SUPPORT ITS CLINICAL-STAGE DEVELOPMENT PROGRAMS BEYOND FIRST HALF OF 2019.ZAFGEN - ‍ENTERED A $20 MILLION VENTURE DEBT FINANCING AGREEMENT WITH SILICON VALLEY BANK ON DEC 29, EXTENDING EXPECTED CASH RUNWAY BEYOND H1 2019​.ZAFGEN INC - TOPLINE DATA ARE EXPECTED IN MID-YEAR 2018 FOR ZGN-1258.ZAFGEN -FOR ZGN-1258,‍ BEGINNING IND APPLICATION-ENABLING WORK IN Q1 FOR FILING WITH U.S. FDA, BEGINNING PHASE 1 CLINICAL DEVELOPMENT BY END OF YEAR​.  Full Article

Zafgen reports Q3 loss per share $0.46
Tuesday, 7 Nov 2017 04:30pm EST 

Nov 7 (Reuters) - Zafgen Inc :Zafgen reports third quarter 2017 financial results.Q3 loss per share $0.46.Q3 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S.Zafgen- continues to expect its cash, cash equivalents and marketable securities balance to be greater than $70 million as of december 31, 2017​.Zafgen Inc - ‍initiated phase 2 clinical trial for second generation metap2 inhibitor ZGN-1061​.  Full Article

Zafgen appoints Jeffrey Hatfield as CEO
Tuesday, 10 Oct 2017 07:00am EDT 

Oct 10 (Reuters) - Zafgen Inc ::Zafgen appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to continue as president, appointed chief scientific officer.Zafgen Inc - Hatfield and Hughes will serve on Zafgen's board of directors​.  Full Article

FDA puts Zafgen's diabetes trial on hold

Zafgen Inc said on Monday the U.S. Food and Drug Administration had placed a clinical hold on U.S. trials of its experimental diabetes drug, citing possible heart safety risks.